Mucormycosis is a potentially fatal opportunistic infection caused by the fungi belonging to the order Mucorales. These fungi are ubiquitous in nature, release airborne spores, and cause necrosis by invading blood vessels. Infection is rare; although humans come in contact with Mucorales, an intact innate immune system is sufficient to prevent infection. Rees et al reported an incidence of 1.7 mucormycosis infections for every 1 million individuals from 1992 to 1993 in 3 California counties.

In a review of 929 mucormycosis cases that occurred between 1940 and 2003, Roden et al reported that the mortality of mucormycosis ranged from 10% to 98%, depending on areas of the body involved. Diabetes was the most common risk factor (found in 36% of cases), followed by hematologic malignancies (17% of cases) and solid organ or hematopoietic cell transplantation (12% of cases). Early treatment is important; a study of 70 patients with mucormycosis revealed that starting amphotericin B more than 6 days after diagnosis resulted in an almost 2-fold increase in mortality at 12 weeks after diagnosis compared with early treatment (83% vs 49%).

In the current report, we present an unusual case of mucormycosis in a patient with AIDS who was receiving steroids.
Report of Case

Presentation and History
A 39-year-old woman with AIDS and no known history of diabetes mellitus was admitted to the emergency department in late September 2012 for weakness, malaise, and dizziness. In August 2012, the patient had been admitted to the emergency department for seizures and a 1.2-cm enhancing calcified lesion with vasogenic edema in the frontal lobe. At that time, neurocysticercosis with cyst rupture was empirically diagnosed after work-up did not reveal any other cause of symptoms. She was discharged with an ongoing treatment regimen of albendazole (200 mg twice daily), dexamethasone (4 mg twice daily), levetiracetam (750 mg twice daily), and insulin (70% human insulin isophane suspension and 30% human insulin, 40 U twice daily). Medications included highly active antiretroviral therapy (combined zidovudine and lamivudine and combined lopinavir and ritonavir) for AIDS. Her last CD4 cell count (taken earlier that month before presentation) was 139 cells/mm³, with an undetectable viral load. Other notable medical history included deep vein thrombosis and gastroesophageal reflux disease.

Physical Examination
At admission, the patient’s vital signs included a temperature of 97.7°F, a pulse of 116 beats/min, a respiration rate of 18 beats/min, and a blood pressure of 98/60 mm Hg. Examination revealed left facial swelling and a protruding left eye that exhibited afferent papillary defect. The patient had vision loss and her left eye was limited in abduction and adduction. The rest of her physical examination was unremarkable.

Laboratory Test Results
At admission, the patient’s metabolic panel revealed the following findings (reference ranges appear in parentheses): blood urea nitrogen, 36 mg/dL (5-20 mg/dL); creatinine, 1.00 mg/dL (0.60-1.00 mg/dL); serum glucose, 250 mg/dL (65-100 mg/dL); chloride, 109 mEq/L (98-107 mEq/L); magnesium, 1.6 mEq/L (1.8-2.4 mEq/L); total protein, 6.0 g/dL (6.4-8.2 g/dL); albumin, 1.6 g/dL (3.4-5.0 g/dL); lactate dehydrogenase, 664 U/L (81-234 U/L); alkaline phosphatase, 149 U/L (50-136 U/L); alanine aminotransferase, 83 U/L (12-78 U/L); and aspartate aminotransferase, 54 U/L (10-37 U/L). Hemoglobin A₁c was 8.8% (4.5%-6.2%).

Thyroid-stimulating hormone level was 0.133 mIU/L (0.510-6.270 mIU/L), total triiodothyronine uptake was 47.53% (22.5%-37.0%), and total thyroxine was 5.20 ng/dL (4.50-10.90 ng/dL).

White blood cell count was 3.9 × 10³ µL (4.5 × 10³ µL to 11.0 × 10³ µL); hemoglobin, 10.5 g/dL (12.0-16.0 g/dL); hematocrit, 31.3% (37.0%-47.0%); and platelet count, 28 × 10³ µL (150 × 10³ µL to 400 × 10³ µL). Differential blood cell count revealed 87.1% neutrophils and 6.2% lymphocytes. Manual differential count showed 87 segmented neutrophils (33-66) and 2 bands (0-10). Absolute neutrophil count was 3855 cells/µL. Total serum iron level was 144 µg/dL (50-175 µg/dL), with a ferritin level of 246 ng/mL (10-291 ng/mL).

Findings from the patient’s urinalysis and blood cultures were unremarkable.

Imaging
One month after admission (October 2012), a chest radiograph revealed no abnormalities. A magnetic resonance image showed new, expansible fluid collection in the left infraorbital fat and opacification of the left maxillary sinus not present at admission (Figure 1). A few opacified left ethmoid air cells were also present. The right frontal, maxillary, and sphenoid sinuses remained clear. No changes were observed in the calcified lesion.

Treatment
The patient was hospitalized and treated for hyperglycemia and thrombocytopenia. She continued to receive steroids and highly active antiretroviral therapy and was evaluated by specialists in the hematology, neurology, ophthalmology, and otolaryngology departments. Bone
CASE REPORT

The results of one study indicated that the incidence of mucormycosis is on the rise in the United States as a result of the increased use of chemotherapy and steroids, which is associated with a prolonged immunocompromised state. According to a study of 5589 transplant patients at the Fred Hutchinson Cancer Center in Seattle, Washington, the number of mucormycosis cases more than doubled from 1985-1989 to 1995-1999.

Mucormycosis in a patient with human immunodeficiency virus (HIV) is rare, but it can be the presenting opportunistic infection in patients with AIDS. Predisposing factors for mucormycosis infection in a patient with HIV include low CD4 count, neutropenia, and

Figure 1.
Magnetic resonance image showing (A) opacification of the left sphenoid sinus and (B) increased intensity of the left orbit suggesting edema in the infraorbital fat.
active intravenous drug use.\textsuperscript{6} In a review\textsuperscript{7} of 10 reported cases of HIV-positive patients with mucormycosis, 8 patients were intravenous drug users and 1 had drug-induced neutropenia.

Although diabetes mellitus is strongly related to mucormycosis, cases of mucormycosis in patients with steroid-induced diabetes mellitus are rare. In a study of 33 patients with mucormycosis who were treated over a 7-year period, only 1 patient had steroid-induced diabetes mellitus.\textsuperscript{8}

Our patient with underlying AIDS who was receiving a high-dose systemic steroid developed invasive mucormycosis. She did not have neutropenia, and she was not an intravenous drug user. In the present case, the combination of immunosuppression and steroid-induced hyperglycemia likely contributed to a relatively higher risk for infection. The patient did not have ketoacidosis related to her hyperglycemia.

**Conclusion**

Mucormycosis is a deadly infection with a high mortality rate. Physicians should maintain a high degree of suspicion for possible invasive fungal infections, including mucormycosis, in patients with underlying immunodeficiency who are receiving high-dose steroid therapy. judicious use of steroids and early detection and treatment could improve outcomes in these patients.

**References**


© 2013 American Osteopathic Association